In 2004, doctors told my husband Mike there was nothing more they could do—the pancreatic cancer he was diagnosed with would soon take his life.
A recent article in JAMA Network Open published by myself and my research collaborators—Jill Harrison at Brown University, Sarah Yarborough at Fred Hutch, and Tammy Stokes at Maury Regional Medical Center—examined the potential for a brief communication-based intervention to help older adults with cancer who live in rural settings better manage their pain.
A study recently published in JAMA sheds light on cancer risks associated with carrying germline CDH1 mutations, challenging previous, potentially inflated, lifetime cancer risk estimates.
At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).
Cancer treatment is steadily improving. The proof can be found in the number of patients with cancer living longer than ever before. Over the next decade, the number of people who have lived five or more years after their diagnosis is projected to increase approximately 30% to 16.3 million.
At the recent ASCO annual meeting, within hematologic malignancies, therapies for multiple myeloma stole the show, comme d’habitude.
In May, the American Society of Clinical Oncology released guidelines on the use of germline genetic testing panels in concert with tumor testing for cancer patients.1
A common perception of genetic screening is that only individuals at high risk of certain diseases will be identified.
Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure.
In 2024, an estimated 6 million pet dogs will be diagnosed with cancer in the United States. As someone who has lost several family dogs to cancer, I know how heartbreaking this diagnosis will be for each of those dogs’ owners.
